Medtech Execs On The Move, October 2013
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.
INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.